Abstract:Background: Autoimmunity might be associated with or implicated in sleep and neurodegenerative disorders. We aimed to describe the features of a novel neurological syndrome associated with prominent sleep dysfunction and antibodies to a neuronal antigen. Methods: In this observational study, we used clinical and video polysomnography to identify a novel sleep disorder in three patients referred to the Sleep Unit of Hospital Clinic, University of Barcelona, Spain, for abnormal sleep behaviours and obstructive sleep apnoea. These patients had antibodies against a neuronal surface antigen, which were also present in five additional patients referred to our laboratory for antibody studies. These five patients had been assessed with polysomnography, which was done in our sleep unit in one patient and the recording reviewed in a second patient. Two patients underwent post-mortem brain examination. Immunoprecipitation and mass spectrometry were used to characterise the antigen and develop an assay for antibody testing. Serum or CSF from 298 patients with neurodegenerative, sleep, or autoimmune disorders served as control samples. Findings: All eight patients (five women; median age at disease onset 59 years [range 52-76]) had abnormal sleep movements and behaviours and obstructive sleep apnoea, as confirmed by polysomnography. Six patients had chronic progression with a median duration from symptom onset to death or last visit of 5 years (range 2-12); in four the sleep disorder was the initial and most prominent feature, and in two it was preceded by gait instability followed by dysarthria, dysphagia, ataxia, or chorea. Two patients had a rapid progression with disequilibrium, dysarthria, dysphagia, and central hypoventilation, and died 2 months and 6 months, respectively, after symptom onset. In five of five patients, video polysomnography showed features of obstructive sleep apnoea, stridor, and abnormal sleep architecture (undifferentiated non-rapid-eye-movement [non-REM] sleep or poorly structured stage N2, simple movements and finalistic behaviours, normalisation of non-REM sleep by the end of the night, and, in the four patients with REM sleep recorded, REM sleep behaviour disorder). Four of four patients had HLA-DRB1*1001 and HLA-DQB1*0501 alleles. All patients had antibodies (mainly IgG4) against IgLON5, a neuronal cell adhesion molecule. Only one of the 298 controls, who had progressive supranuclear palsy, had IgLON5 antibodies. Neuropathology showed neuronal loss and extensive deposits of hyperphosphorylated tau mainly involving the tegmentum of the brainstem and hypothalamus in the two patients studied. Interpretation: IgLON5 antibodies identify a unique non-REM and REM parasomnia with sleep breathing dysfunction and pathological features suggesting a tauopathy. Funding: Fondo de Investigaciones Sanitarias, Centros de Investigación Biomédica en Red de enfermedades neurodegenerativas (CIBERNED) and Respiratorias (CIBERES), Ministerio de Economía y Competitividad, Fundació la Marató TV3, and the National Institutes of Health.

The Sleep Disorder in Anti-lgLON5 Disease

Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease

Anti-IgLON 5 Disease

New knowledge on anti-IgLON5 disease

P014 IgLON5 Disease – A Review of 2 Cases and Sleep Manifestations

A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study

Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature

Upper airway manifestations of anti-IgLON5 disease: Otorhinolaryngological point of view

Atypical neurological manifestations in anti-IgLON5 disease: a case report

Neuropathological criteria of anti-IgLON5-related tauopathy

Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review

Clinical presentations and antibody mechanisms in anti-IgLON5 disease

Anti-IgLON5 disease: A case with intestinal obstruction and peripheral neuropathy

Anti-IgLON5 disease with severe central sleep apnea-hypopnea syndrome: A case report

IgLON5-IgG: Innocent Bystander or Perpetrator?

Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

Case Report: Neuropsychological Findings in IgLON5 Antibody Disorder

Patients’ IgLON5 autoantibodies interfere with IgLON5-protein interactions

IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder: A Multicenter Study

Red flags and symptom overlap in anti‐IgLON5 disease and dementia with Lewy bodies – a systematic review

Expanding the Clinical Spectrum of Anti-Iglon5 Disease: A Multicenter Retrospective Study